Leiden University Medical Center, Department of Orthopaedics, Albinusdreef 2, Leiden, 2333 ZA, The Netherlands.
Leiden University Medical Center, Department of Orthopaedics, Albinusdreef 2, Leiden, 2333 ZA, The Netherlands; Department of Orthopaedic Surgery, Joint Research, OLVG, Amsterdam, The Netherlands.
J Clin Epidemiol. 2024 Nov;175:111516. doi: 10.1016/j.jclinepi.2024.111516. Epub 2024 Sep 5.
High-quality data entry in clinical trial databases is crucial to the usefulness, validity, and replicability of research findings, as it influences evidence-based medical practice and future research. Our aim is to assess the quality of self-reported data in trial registries and present practical and systematic methods for identifying and evaluating data quality.
We searched ClinicalTrials.Gov (CTG) for interventional total knee arthroplasty (TKA) trials between 2000 and 2015. We extracted required and optional trial information elements and used the CTG's variables' definitions. We performed a literature review on data quality reporting on frameworks, checklists, and overviews of irregularities in healthcare databases. We identified and assessed data quality attributes as follows: consistency, accuracy, completeness, and timeliness.
We included 816 interventional TKA trials. Data irregularities varied widely: 0%-100%. Inconsistency ranged from 0% to 36%, and most often nonrandomized labeled allocation was combined with a "single-group" assignment trial design. Inaccuracy ranged from 0% to 100%. Incompleteness ranged from 0% to 61%; 61% of finished TKA trials did not report their outcome. With regard to irregularities in timeliness, 49% of the trials were registered more than 3 months after the start date.
We found significant variations in the data quality of registered clinical TKA trials. Trial sponsors should be committed to ensuring that the information they provide is reliable, consistent, up-to-date, transparent, and accurate. CTG's users need to be critical when drawing conclusions based on the registered data. We believe this awareness will increase well-informed decisions about published articles and treatment protocols, including replicating and improving trial designs.
临床试验数据库中高质量的数据录入对于研究结果的有用性、有效性和可重复性至关重要,因为它影响基于证据的医疗实践和未来的研究。我们的目的是评估试验注册中自我报告数据的质量,并提出实用且系统的方法来识别和评估数据质量。
我们在 ClinicalTrials.Gov(CTG)中搜索了 2000 年至 2015 年期间的干预性全膝关节置换术(TKA)试验。我们提取了必需和可选的试验信息要素,并使用 CTG 的变量定义。我们对数据质量报告框架、检查表和医疗保健数据库中不规则性的概述进行了文献回顾。我们确定并评估了数据质量属性,包括一致性、准确性、完整性和及时性。
我们纳入了 816 项干预性 TKA 试验。数据不规则性差异很大:0%-100%。不一致性范围从 0%到 36%,最常见的是将非随机标记的分配与“单组”分配试验设计相结合。不准确性范围从 0%到 100%。不完整性范围从 0%到 61%;61%的完成 TKA 试验未报告其结局。关于及时性的不规则性,49%的试验在开始日期后超过 3 个月注册。
我们发现注册的临床 TKA 试验的数据质量存在显著差异。试验赞助商应致力于确保他们提供的信息是可靠、一致、最新、透明和准确的。CTG 的用户在基于注册数据得出结论时需要持批评态度。我们相信,这种意识将增加对已发表文章和治疗方案的明智决策,包括复制和改进试验设计。